Hypera SA operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Hypera SA with three other
pharmaceutical manufacturers in Latin America:
Instituto Hermes Pardini SA
(2020
sales of 1.49 billion Brazilian Reals [US$279.72 million]
of which 100%
was auxiliary diagnostic support services),
Genomma Lab Internacional Sab De Cv
of MEXICO
(13.87 billion Mexican Pesos [US$695.59 million]
of which 100%
was PC), and
Fleury SA
(2.97 billion Brazilian Reals [US$556.38 million]
of which 82%
was Diagnostic Medicine).
Sales Analysis.
During the second
quarter of 2021, sales at Hypera SA totalled
1.51 billion Brazilian Reals.
This is
an increase of 43.5%
from the 1.05 billion Brazilian Reals in sales at the company during the second quarter of 2020.
During the first two
quarters of 2021, sales totalled 2.68 billion Brazilian Reals, which is
43.6% higher
than through the first two quarters of 2020.
During the previous 9 quarters, sales at Hypera SA have increased compared with the same quarter in the previous year.
Hypera SA reported sales of 4.09 billion Brazilian Reals (US$765.56 million)
for the
year ending
December of 2020.
This
represents
an
increase of 24.1%
versus 2019, when the company's sales were 3.29 billion Brazilian Reals.